Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
Adult
Aged
Anti-Infective Agents
/ therapeutic use
Azithromycin
/ therapeutic use
Betacoronavirus
/ drug effects
C-Reactive Protein
/ metabolism
COVID-19
Coronavirus Infections
/ diagnostic imaging
Disease Progression
Drug Combinations
Female
Humans
Hydroxychloroquine
/ therapeutic use
Intensive Care Units
Lopinavir
/ therapeutic use
Male
Middle Aged
Multivariate Analysis
Pandemics
Pneumonia, Viral
/ diagnostic imaging
Prognosis
Retrospective Studies
Ritonavir
/ therapeutic use
SARS-CoV-2
Survival Analysis
T-Lymphocytes
/ pathology
Tomography, X-Ray Computed
Treatment Outcome
Covid-19
azithromycin
hydroxychloroquine
pneumonia
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
06
05
2020
revised:
24
07
2020
accepted:
28
07
2020
pubmed:
7
8
2020
medline:
2
10
2020
entrez:
7
8
2020
Statut:
ppublish
Résumé
The effect of anti-infective agents in COVID-19 is unclear. The impact of changes in practice on prognosis over time has not been evaluated. Single center, retrospective study in adults hospitalized in a medicine ward for COVID-19 from March 5 A total of 132 patients were admitted: mean age 59.0±16.3 years; mean C-reactive protein (CRP) level 84.0±71.1 mg/L; 46% had a lymphocyte count <1000/mm The present study showed a significant decrease in admission to ICU over time, which was probably related to multiple factors, including a better indication of pulmonary CT-scan, oxygen therapy, and a suitable prescription of anti-infective agents.
Identifiants
pubmed: 32755653
pii: S0924-8579(20)30312-5
doi: 10.1016/j.ijantimicag.2020.106129
pmc: PMC7396133
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Drug Combinations
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
C-Reactive Protein
9007-41-4
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106129Informations de copyright
Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Int J Infect Dis. 2020 Aug;97:396-403
pubmed: 32623082
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
JAMA Netw Open. 2020 Apr 24;3(4):e208857
pubmed: 32330277
Lancet. 2020 Jun 6;395(10239):1760-1761
pubmed: 32464114
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
JAMA. 2015 Nov 17;314(19):2034-2044
pubmed: 26575060
Sci Rep. 2020 Aug 4;10(1):13093
pubmed: 32753646
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
BMJ. 2020 May 14;369:m1844
pubmed: 32409486
Travel Med Infect Dis. 2020 May - Jun;35:101738
pubmed: 32387409
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
J Antimicrob Chemother. 2011 May;66(5):959-63
pubmed: 21406435
J Antibiot (Tokyo). 2019 Oct;72(10):759-768
pubmed: 31300721
Int J Antimicrob Agents. 2020 Jun;55(6):105982
pubmed: 32305588
Stem Cell Rev Rep. 2020 Jun;16(3):434-440
pubmed: 32307653